Stifel Maintains Buy on Soleno Therapeutics, Raises Price Target to $74
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Dae Gon Ha has maintained a Buy rating on Soleno Therapeutics and raised the price target from $59 to $74.
October 01, 2024 | 5:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Dae Gon Ha has maintained a Buy rating on Soleno Therapeutics and increased the price target from $59 to $74, indicating a positive outlook.
The increase in the price target from $59 to $74 by Stifel suggests a positive outlook for Soleno Therapeutics, likely leading to a short-term increase in stock price as investors react to the analyst's confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100